APA

Cappuzzo F., Novello S., De Marinis F., Selvaggi G., Scagliotti G. V., Barbieri F., Maur M., Papi M., Pasquini E., Bartolini S., Marini L. & Crinò L. (20061025). A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. : Lung cancer (Amsterdam, Netherlands).

Chicago

Cappuzzo F, Novello S, De Marinis F, Selvaggi G, Scagliotti G V, Barbieri F, Maur M, Papi M, Pasquini E, Bartolini S, Marini L and Crinò L. 20061025. A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. : Lung cancer (Amsterdam, Netherlands).

Harvard

Cappuzzo F., Novello S., De Marinis F., Selvaggi G., Scagliotti G. V., Barbieri F., Maur M., Papi M., Pasquini E., Bartolini S., Marini L. and Crinò L. (20061025). A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. : Lung cancer (Amsterdam, Netherlands).

MLA

Cappuzzo F, Novello S, De Marinis F, Selvaggi G, Scagliotti G V, Barbieri F, Maur M, Papi M, Pasquini E, Bartolini S, Marini L and Crinò L. A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. : Lung cancer (Amsterdam, Netherlands). 20061025.